Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Dendritic Cells Subsets Profiles in Classical Hodgkin Lymphoma at Diagnosis and upon Treatment Completion: Analysis on 54 Patients

Domenico Galati, MD PhD, Serena Zanotta, ScD, Gaetano Corazzelli, MD, Bruzzese Dario, PhD, Gaetana Capobianco, MD, Emanuela Morelli, MD, Manuela Arcamone, MD, Ferdinando Frigeri, MD, Rosaria De Filippi, MD PhD, Antonio Pinto, MD

Blood (2017) 130 (Supplement 1): 4095.

https://doi.org/10.1182/blood.V130.Suppl_1.4095.4095

Published: 2017

Journal Articles

Edo-S101, a Bendamustine (BDM)/ Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Demonstrates Potent Preclinical Activity Against T-Cell Malignancies and Overcomes BDM-Resistance

Rosaria De Filippi, MD PhD, Stefania Crisci, ScD, Sara Mele, BS, Serena Zanotta, ScD, Gaetano Corazzelli, MD, Domenico Galati, MD PhD, Davide Coppola, RN, Piera Maiolino, PharmD, Mariangela Saggese, PharmD, Francesco Volzone, MD, Emanuela Morelli, MD, Daniela Donnarumma, MD, Gianpaolo Marcacci, MD, Ferdinando Frigeri, MD, Niels Odum, MD, Thomas Mehrling, MD PhD, Antonio Pinto, MD

Blood (2017) 130 (Supplement 1): 2547.

https://doi.org/10.1182/blood.V130.Suppl_1.2547.2547

Published: 2017

Journal Articles

Continuous Exposure to Bendamustine (BDM) Results in Stable Upregulation of CD30 and Increased Sensitivity to Brentuximab Vedotin (BV) in Tumor Cells of Hodgkin Lymphoma (HL)

Rosaria De Filippi, MD PhD, Michele Cillo, ScD, Stefania Crisci, ScD, Sara Mele, BS, Serena Zanotta, ScD, Angela De Monaco, ScD, Domenico Galati, MD, Giancarla Iaccarino, ScD, Raffaele Di Francia, ScD, Emanuela Morelli, MD, Gianpaolo Marcacci, MD, Cristina Becchimanzi, MD, Attilio Guarini, MD, Ferdinando Frigeri, MD PhD, Gaetano Corazzelli, MD, Antonello Pinto, MD

Blood (2015) 126 (23): 2479.

https://doi.org/10.1182/blood.V126.23.2479.2479

Published: 2015

Journal Articles

Lenalidomide in Combination with Bendamustine for Patients with Chemorefractory Hodgkin Lymphoma: Final Results of the Leben Multicenter Phase 1/2 Study

Antonello Pinto, MD, Vincenzo Pavone, MD, Francesco Angrilli, MD, Mariangela Saggese, PharmD, Stefania Crisci, ScD, Caterina Patti, MD, Pier Luigi Zinzani, MD PhD, Alfonso Maria D'Arco, MD, Elena Cavalieri, MD, Attilio Guarini, MD, Michele Spina, MD, Daniela Carlino, MD, Simona Falorio, MD, Emanuela Morelli, MD, Manuela Arcamone, MD, Ferdinando Frigeri, MD PhD, Annarosaria De Chiara, MD, Rosaria De Filippi, MD PhD, Gaetano Corazzelli, MD

Blood (2015) 126 (23): 1541.

https://doi.org/10.1182/blood.V126.23.1541.1541

Published: 2015

Journal Articles

The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia

Fortunato Morabito, Rosaria De Filippi, Luca Laurenti, Katja Zirlik, Anna Grazia Recchia, Massimo Gentile, Emanuela Morelli, Ernesto Vigna, Vincenzo Gigliotti, Rosa Calemma, Barbara Amoroso, Antonino Neri, Giovanna Cutrona, Manlio Ferrarini, Stefano Molica, Giovanni Del Poeta, Claudio Tripodo, Antonio Pinto

Blood (2011) 118 (24): 6353–6361.

https://doi.org/10.1182/blood-2011-04-345587

Published: 2011

Includes: Supplemental data

Journal Articles

Peptide Nucleic Acid (PNA)-Clamping Competitive PCR: A New Tool for the High Sensitive Detection of JAK2V617F Mutation in Myeloproliferative Neoplasms (MPNs)

Ferdinando Frigeri, MD, PhD, Raffaele Di Francia, PhD, Luigi Petraccone, PhD, Concetta Giancola, PhD, Annunziata Cummaro, PhD, Paolo Danise, MD, Stefania Crisci, PhD, Giancarla Iaccarino, PhD, Rosaria De Filippi, MD, PhD, Emanuela Morelli, MD, Gaetana Capobianco, MD, Francesco Volzone, MD, Alfonso Maria D'Arco, MD, Antonio Pinto, MD

Blood (2011) 118 (21): 5168.

https://doi.org/10.1182/blood.V118.21.5168.5168

Published: 2011

Journal Articles

Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial.

Gaetano Corazzelli, MD, Ferdinando Frigeri, MD, Gianpaolo Marcacci, MD, Cristina Becchimanzi, MD, Gaetana Capobianco, MD, Manuela Arcamone, MD, Emanuela Morelli, MD, Francesco Volzone, MD, Filippo Russo, MD, Antonio Pinto, MD

Blood (2010) 116 (21): 2829.

https://doi.org/10.1182/blood.V116.21.2829.2829

Published: 2010

Journal Articles

The Total Amount of Kappa Plus Lambda Serum Immunoglobulin Free Light Chains (sFLC κ+λ) Is a Powerful Independent Predictor of Time to First Treatment In Chronic Lymphocytic Leukemia (CLL) and Allows Definition of a Novel Prognostic Scoring System: A Study of 449 Therapy-naïve Patients

Fortunato Morabito, MD, Rosaria De Filippi, MD, PhD, Luca Laurenti, MD, Katja Zirlik, MD, Anna Grazia Recchia, PhD, Massimo Gentile, MD, Emanuela Morelli, MD, Solluzzo Cavalcanti, MD, Giancarla Iaccarino, D.Sci, Barbara Amoroso, MD, PhD, Antonino Neri, MD, Giovanna Cutrona, PhD, Manlio Ferrarini, MD, Stefano Molica, MD, Giovanni Del Poeta, MD, Antonio Pinto, MD

Blood (2010) 116 (21): 2437.

https://doi.org/10.1182/blood.V116.21.2437.2437

Published: 2010

NARROW

Dendritic Cells Subsets Profiles in Classical Hodgkin Lymphoma at Diagnosis and upon Treatment Completion: Analysis on 54 Patients

Edo-S101, a Bendamustine (BDM)/ Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Demonstrates Potent Preclinical Activity Against T-Cell Malignancies and Overcomes BDM-Resistance

Continuous Exposure to Bendamustine (BDM) Results in Stable Upregulation of CD30 and Increased Sensitivity to Brentuximab Vedotin (BV) in Tumor Cells of Hodgkin Lymphoma (HL)

Lenalidomide in Combination with Bendamustine for Patients with Chemorefractory Hodgkin Lymphoma: Final Results of the Leben Multicenter Phase 1/2 Study

The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia

Peptide Nucleic Acid (PNA)-Clamping Competitive PCR: A New Tool for the High Sensitive Detection of JAK2V617F Mutation in Myeloproliferative Neoplasms (MPNs)

Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial.

The Total Amount of Kappa Plus Lambda Serum Immunoglobulin Free Light Chains (sFLC κ+λ) Is a Powerful Independent Predictor of Time to First Treatment In Chronic Lymphocytic Leukemia (CLL) and Allows Definition of a Novel Prognostic Scoring System: A Study of 449 Therapy-naïve Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only